|Bid||3.9600 x 2200|
|Ask||4.2000 x 1400|
|Day's Range||3.9300 - 4.1700|
|52 Week Range||2.2500 - 7.7800|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2021 - Nov 08, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.40|
Subscribe to Yahoo Finance Plus to view Fair Value for LQDA
What happened Liquidia Technologies (NASDAQ: LQDA) stock went on quite a ride during Thursday's trading session. On the back of a new analyst take on the company, its shares climbed almost 22% higher in early action before settling down to a gain of slightly over 10% on the day.
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
United Therapeutics saw its stock jump after receiving approval from the FDA to launch a new treatment for pulmonary arterial hypertension. Liquidia is pursuing a similar drug.